10-K: Surrozen Reports Increased Losses, Advances Ophthalmology Pipeline

Surrozen, Inc. reported a significant increase in net losses for 2025, driven by non-cash charges and increased R&D, while advancing its Wnt-pathway ophthalmology pipeline and securing new financing.

Summary

• Net loss for the year ended December 31, 2025, was $242.0 million, a substantial increase from $63.6 million in 2024.
• Total revenue decreased to $3.477 million in 2025 from $10.655 million in 2024, primarily due to the recognition of a $10.0 million milestone in 2024.
• Research and development expenses increased by 39% to $29.365 million in 2025, mainly due to higher manufacturing costs, lab expenses, and consulting fees for ophthalmology programs.
• General and administrative expenses increased by 8% to $16.204 million in 2025, driven by professional service fees.
• The company discontinued development of SZN-043 in severe alcohol associated hepatitis in Q1 2025 due to insufficient early clinical benefit.
• SZN-8141 (Fzd4 agonism + VEGF antagonism) is being developed for diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD), with an IND submission anticipated in the second half of 2026.
• SZN-8143 (Fzd4 agonism + VEGF antagonism + IL-6 antagonism) is being developed for DME, wet AMD, and uveitic macular edema (UME).
• Boehringer Ingelheim made a $10.0 million milestone payment in September 2024 for SZN-413 development and a $5.0 million research milestone payment in March 2026 for a positive IND-enabling GLP toxicology study.
• The company secured $74.7 million in net proceeds from the first tranche of a $175.0 million two-tranche private placement (2025 PIPE) in March 2025, with an additional $3.3 million net from an optional closing in December 2025.
• A second tranche of the 2025 PIPE, totaling $95.1 million gross, is contingent upon FDA clearance of the SZN-8141 IND application by October 31, 2026.
• An At-the-Market (ATM) program generated $9.1 million in net proceeds by December 31, 2025, with an additional $26.9 million net in January 2026, before the program was terminated and a new $50.0 million ATM was established in March 2026.
• Cash and cash equivalents stood at $89.2 million as of December 31, 2025, with an accumulated deficit of $527.3 million.
• Merck filed a post-grant review petition in February 2026 challenging a U.S. patent (No. 12,297,278) related to Surrozen's SWAP platform.
• The strategic research collaboration with TCGFB, Inc. was terminated effective November 13, 2025, leading to a $0.9 million impairment charge on a warrant asset due to TCGFB's dissolution.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with cautious optimism. While the significant increase in net loss and revenue decline are concerning, a large portion of the loss is non-cash. The positive milestones from the Boehringer Ingelheim collaboration and successful capital raises provide crucial validation and funding for the promising ophthalmology pipeline, despite the inherent high risks of early-stage biotech development and a new patent challenge.

Positives

• Boehringer Ingelheim's decision to advance SZN-413 triggered a $10.0 million milestone payment in September 2024, validating the SWAP technology and SZN-413's potential.
• A further $5.0 million research milestone payment was received from Boehringer Ingelheim in March 2026, following a positive IND-enabling GLP toxicology study for SZN-413.
• Successful capital raises through the 2025 PIPE ($74.7 million net from first tranche, $3.3 million net from optional closing) and the 2025 ATM ($9.1 million net by Dec 2025, $26.9 million net in Jan 2026) provide funding for ongoing operations and pipeline development.
• The company maintains a clear strategic focus on ophthalmology, an area with strong genetic and biologic validation for Wnt signaling and high unmet medical need.
• Preclinical data for SZN-8141 and SZN-8143 demonstrated stimulation of Wnt signaling, induction of normal retinal vessel regrowth, and suppression of pathological vessel growth, with SZN-8141 also showing a significant reduction in avascular area and neovascularization in a retinopathy model.
• Research programs in corneal endothelial disease showed enhanced proliferation of human corneal endothelial cells, wound healing, and improved corneal clarity in preclinical models, indicating platform versatility.

Negatives

• Net loss significantly increased to $242.0 million in 2025 from $63.6 million in 2024, largely due to non-cash charges related to warrant and tranche liability revaluation, but also increased operating expenses.
• Total revenue decreased by 67% in 2025 compared to 2024, primarily due to the timing of milestone recognition.
• The discontinuation of SZN-043 development in severe alcohol associated hepatitis in Q1 2025 indicates a setback in a clinical program due to insufficient clinical benefit.
• The termination of the strategic research collaboration with TCGFB, Inc. and subsequent dissolution of TCGFB resulted in a $0.9 million impairment charge on a warrant asset.
• The company has an accumulated deficit of $527.3 million as of December 31, 2025, highlighting a history of significant operating losses and the need for substantial future funding.
• Merck's post-grant review petition challenging a key U.S. patent related to the SWAP platform introduces intellectual property risk and potential litigation costs.

Risks

• The company has a history of losses and expects to incur significant losses for the foreseeable future, potentially never achieving or maintaining profitability.
• Substantial additional funds are needed to advance product candidates, and there is no guarantee of sufficient future funding, which could lead to delays or discontinuation of development programs.
• None of the product candidates have received regulatory approval, and profitability depends on successful approval and commercialization, which is a lengthy, expensive, and uncertain process.
• Product candidates may demonstrate undesirable safety or tolerability side effects (e.g., tumor formation, transaminase elevations) during clinical trials or after approval, potentially compromising marketability or leading to regulatory action.
• Future equity or debt issuances will likely dilute existing stockholders' ownership interests.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing introduces risks of unsatisfactory performance, delays, or supply interruptions.
• Clinical development activities could be delayed due to patient enrollment difficulties, regulatory requirements, manufacturing challenges, or unforeseen safety issues.
• The manufacturing process for product candidates is complex and susceptible to issues like contamination, equipment failure, and difficulties in scaling production.
• The company faces intense competition from major pharmaceutical and biotechnology companies with significantly greater financial resources and expertise.
• Inability to maintain proper and effective internal controls over financial reporting could adversely affect financial reporting accuracy and stock price.
• Limitations on the ability to use net operating loss carryforwards (NOLs) due to ownership changes could increase future tax liabilities.
• Inability to attract and retain qualified key management, technical personnel, and employees would impair business plan implementation.
• Difficulties in managing growth and expanding operations could arise as product candidates advance.
• Inability to develop internal sales, marketing, and distribution capabilities or secure favorable third-party agreements could hinder commercialization.
• International operations expose the company to business, political, operational, and financial risks, including varying regulatory requirements and reduced intellectual property protection.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, financial condition, and prospects.
• Significant product liability risks are inherent in the development, testing, manufacturing, and marketing of product candidates, with potentially insufficient insurance coverage.
• Risk of fraud or other misconduct by employees, principal investigators, consultants, and commercial collaborators, including noncompliance with regulatory standards and healthcare fraud and abuse laws.
• Failure to comply with health and data protection laws and regulations (e.g., HIPAA, GDPR, CCPA, CPRA) could lead to enforcement actions, litigation, or reputational harm.
• Dependence on sophisticated information technology systems and data processing makes the company vulnerable to security or data privacy breaches.
• Non-compliance with environmental, health, and human safety laws and regulations could result in substantial costs, fines, or penalties.
• Health epidemics, natural disasters, and other events could adversely affect manufacturing, clinical trials, and other business activities.
• Dependence on collaborations for development and commercialization means success is tied to collaborators' performance and strategic priorities.
• Inability to obtain or protect intellectual property rights (patents, trade secrets) or challenges to existing IP could impair competitive position and commercialization efforts.
• In-licensed intellectual property may be subject to government 'march-in rights' or U.S. manufacturing requirements.
• Stock price volatility is expected due to various factors, including clinical trial results, regulatory developments, and market conditions.
• A few stockholders, including one director, control a large portion of voting rights, potentially influencing decisions adversely to other stockholders.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to choose a favorable judicial forum.
• Claims for indemnification by directors and officers may reduce available funds.
• The company's status as a smaller reporting company may make its securities less attractive due to reduced disclosure obligations.
• The company may redeem unexpired public warrants prior to their exercise at a disadvantageous time, making them worthless.

Future Outlook

The company anticipates continued significant operating losses for the foreseeable future as it expands its pipeline and advances product candidates through clinical development and regulatory submissions. An Investigational New Drug (IND) application for SZN-8141 is expected to be submitted in the second half of 2026. The second tranche of the 2025 PIPE, expected to provide $95.1 million in gross proceeds, is contingent on FDA clearance of the SZN-8141 IND by October 31, 2026, and is intended to fund multiple ophthalmology programs through initial Phase 1 studies. The company expects to require additional capital in the long-term, potentially through equity offerings, debt financings, or strategic collaborations, to fund operations until it can generate revenue from product sales.

Management Comments

• Our mission is to transform the treatment of serious ophthalmic disease by fully exploiting the Wnt pathway.
• We believe our approach has the potential to change the treatment paradigm for ophthalmic disease and substantially impact patient outcomes.
• We believe that ophthalmology indications are particularly well-suited for Wnt modulating therapeutics due to the combination of strong genetic and biologic validation and the need for approaches to restore tissue structure and function.
• We believe we are potentially the first developer to manufacture synthetic, soluble Wnt mimetics.
• We consider ourselves to be pioneers in the selective modulation of the Wnt signaling pathway and intend to utilize our proprietary insights into Wnt biology and our proprietary technologies to further advance our research and exploration of its therapeutic potential.

Industry Context

StockSavvy.ai notes that Surrozen operates in the highly competitive biotechnology and pharmaceutical industries, particularly within ophthalmology, where Wnt pathway modulation is gaining traction for tissue repair. The current standard of care for major retinal diseases like DME and wet AMD involves anti-VEGF therapies, with market leaders such as Roche's Vabysmo generating over $5 billion in global revenue in 2025, and branded anti-VEGF therapies collectively exceeding $13 billion. This indicates a substantial market but also intense competition. Merck's investigational tri-specific Wnt agonist antibody, MK-3000, in Phase 2/3 trials for DME and wet AMD, and Roche's acquisition of AntlerA Therapeutics, underscore the industry's growing interest in Wnt-targeting therapeutics. Surrozen's strategy to combine Fzd4 agonism with VEGF and/or IL-6 antagonism in SZN-8141 and SZN-8143 aims to differentiate its candidates by offering potentially superior benefits over existing single-agent therapies and addressing unmet needs related to efficacy duration and dosing frequency.

Comparison to Industry Standards

• Current standard of care for diabetic macular edema (DME), retinal vein occlusion, and wet age-related macular degeneration (wet AMD) primarily involves intravitreal administration of anti-VEGF therapies, including monotherapies and dual-pathway agents like Vabysmo (Roche).
• Vabysmo, a bispecific antibody inhibiting VEGF and Ang-2, generated over $5 billion in global revenue in 2025, demonstrating non-inferiority to aflibercept in clinical studies and improvements in anatomic measures and less frequent dosing.
• Merck's MK-3000, a Fzd4 monotherapy, has shown proof of concept in DME clinical trials with visual acuity improvements comparable to anti-VEGF therapies, indicating direct competition in Wnt pathway modulation for retinal diseases.
• An IL-6 antagonist has achieved its primary endpoint on best-corrected visual acuity (BCVA) in a pivotal Phase 3 study for uveitic macular edema (UME), suggesting a validated target for Surrozen's SZN-8143 which includes IL-6 antagonism.
• Surrozen's SZN-8141 and SZN-8143 aim to differentiate by combining Fzd4 agonism with VEGF antagonism (and IL-6 antagonism for SZN-8143), potentially offering synergistic benefits over single-agent therapies and addressing limitations of existing treatments in terms of duration of efficacy and frequent dosing.

Corporate Governance

Legal Proceedings

• Merck filed a post-grant review petition with the U.S. Patent Trial and Appeal Board in February 2026, challenging Surrozen's U.S. Patent No. 12,297,278, which claims certain multispecific, tetravalent Wnt surrogate molecules related to the SWAP platform.

Related Party Transactions

• The strategic research collaboration with TCGFB, Inc., entered in October 2024 and terminated in November 2025, was a related party transaction because entities affiliated with The Column Group (a significant stockholder) founded and controlled TCGFB, and Dr. Kutzkey (a director) serves as Managing Partner of The Column Group.
• A sublease agreement with Nura Bio, Inc., entered in April 2024 and extended in July 2025 until May 2026, is a related party transaction because Tim Kutzkey (a director) serves as chairman of Nura Bio's board, and The Column Group (a significant stockholder) is affiliated with Nura Bio.
• The 2024 Private Placement in April 2024 included the issuance and sale of common stock and warrants to certain members of management.

Stakeholder Impact

• Shareholders face significant dilution from recent and planned equity capital raises (2025 PIPE, ATM programs).
• Shareholders are exposed to high stock price volatility due to the early stage of product development and inherent risks in the biotechnology industry.
• Employees benefit from competitive compensation, equity grants, and a new Severance and Change in Control Plan, enhancing retention and recruitment.
• Future patients could benefit from novel Wnt-pathway modulating therapeutics for serious ophthalmic diseases with high unmet medical needs, such as DME, wet AMD, and UME.
• The company's reliance on third-party manufacturers and CROs impacts suppliers and collaborators, requiring strong contractual relationships and performance.
• Creditors and investors face risks associated with the company's substantial accumulated deficit and ongoing need for additional funding to sustain operations and advance its pipeline.

Next Steps

• Submit an Investigational New Drug (IND) application for SZN-8141 in the second half of 2026.
• Achieve FDA clearance for the SZN-8141 IND by October 31, 2026, to trigger the second tranche of the 2025 PIPE funding ($95.1 million gross).
• Continue preclinical and clinical development of SZN-8141 and SZN-8143 for retinal diseases.
• Further evaluate additional ophthalmology research programs targeting Wnt signaling for retinal and corneal diseases.
• Potentially pursue strategic alliances to accelerate product development and maximize commercial potential.
• Respond to Merck's post-grant review petition challenging U.S. Patent No. 12,297,278 related to the SWAP platform.
• Continue efforts to attract and retain qualified scientific, clinical, and management personnel.
• Implement improvements to operational, financial, and management controls and reporting systems.

Key Dates

Recommendation

A 'hold' recommendation is appropriate for Surrozen, Inc. given the mixed signals in this filing. While the company reported a significantly increased net loss and decreased revenue, a substantial portion of the loss is non-cash, and the operating loss, though higher, is typical for a clinical-stage biotech. The positive milestones from the Boehringer Ingelheim collaboration provide strong external validation for the Wnt platform and SZN-413, and recent capital raises have bolstered liquidity. However, the discontinuation of SZN-043 and the new patent challenge by Merck introduce additional risks. Investors should await further definitive clinical data for SZN-8141 and SZN-8143, and monitor the outcome of the patent dispute, before making a more decisive investment move.

Keywords

Biotechnology, Ophthalmology, Wnt pathway, Tissue repair, Retinal diseases, Diabetic macular edema, Wet age-related macular degeneration, Uveitic macular edema, Antibody therapeutics, SWAP technology, SZN-8141, SZN-8143, SZN-413, Clinical trials, Preclinical development, Regulatory approval, SEC filing, 10-K, Biopharmaceutical, Drug development, Intellectual property, Capital raise, Boehringer Ingelheim, VEGF antagonism, IL-6 antagonism, Fzd4 agonism